{
    "clinical_study": {
        "@rank": "35058", 
        "arm_group": [
            {
                "arm_group_label": "Corticosteroid"
            }, 
            {
                "arm_group_label": "non-corticosteroid group"
            }
        ], 
        "brief_summary": {
            "textblock": "Corticosteroid treatment in diabetic patients admitted for COPD exacerbation are expected to\n      significantly increase hemoglobin A1C levels"
        }, 
        "brief_title": "Corticosteroids and Hemoglobin A1C Levels in Diabetic Patients With COPD Exacerbation", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Chronic Obstructive Pulmonary Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "detailed_description": {
            "textblock": "HbA1C levels were evaluated in diabetic patients with COPD exacerbation on admission to the\n      hospital and 3-months later. Demographic, clinical, laboratory variables and total steroid\n      dose were documented. Age- and sex-matched group of diabetic patients with COPD who were\n      admitted for other reasons, were asked to participate as a control group. Mann-Whitney and\n      Chi square/Fischer's exact tests were used to compare between the parameters of the two\n      groups. Wilcoxon signed rank test was used to compare between HbA1C levels at baseline and 3\n      months later. Multi-variate linear regression analysis was used to find predictors for\n      increase in HbA1C levels in the patients' group."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diabetic patients with COPD exacerbation\n\n        Exclusion Criteria:\n\n          -  Patients treated with steroids during the previous 3 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Diabetic patients with COPD ecaxerbation who are admitted to the hospital"
            }
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01798420", 
            "org_study_id": "Hb-A1C-2012"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "COPD", 
            "Diabetes", 
            "steroids", 
            "Hemoglobin A1C DIFFERENCE"
        ], 
        "lastchanged_date": "February 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nzareth", 
                    "country": "Israel", 
                    "state": "Nazareth", 
                    "zip": "16000"
                }, 
                "name": "Department of medicine"
            }
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_groups": "2", 
        "official_title": "The Impact of Corticosteroid Treatment on Hemoglobin A1C Levels in Diabetic Patients With COPD Exacerbation", 
        "other_outcome": {
            "measure": "Weight", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Hemoglobin A1C LEVEL", 
            "safety_issue": "No", 
            "time_frame": "3 MONTHS"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01798420"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The Nazareth Hospital, Israel", 
            "investigator_full_name": "George Habib", 
            "investigator_title": "Head, Rheumatology clinic, Nzareth hospital, Nzareth", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Glucose levels", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "source": "The Nazareth Hospital, Israel", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The Nazareth Hospital, Israel", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2013"
    }
}